Ask about this productRelated genes to: SARS2 antibody
- Gene:
- SARS2 NIH gene
- Name:
- seryl-tRNA synthetase 2, mitochondrial
- Previous symbol:
- SARSM
- Synonyms:
- FLJ20450, mtSerRS, SerRSmt, SARS, SERS, SYS
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-10-09
- Date modifiied:
- 2016-11-09
Related products to: SARS2 antibody
Related articles to: SARS2 antibody
- Critically ill COVID-19 patients frequently develop organ dysfunction and acute brain dysfunction with features overlapping sepsis-associated encephalopathy (SAE). Real-world cohorts from Eastern European intensive care during the pre-vaccination period are scarce. - Source: PubMed
Publication date: 2026/06/30
Neacsu Alexandru IonutRotaru-Zavaleanu Alexandra-DanielaNovac Marius-BogdanRadu LucretiuOsiac Eugen - A considerable proportion of patients experience post-acute sequelae of COVID-19 (PASC). Increasing evidence suggests sex-related differences, yet systematic longitudinal analyses remain limited. This study aimed to examine sex-specific differences in symptoms, psychological burden, work productivity and physical activity over ten months following acute COVID-19. - Source: PubMed
Publication date: 2026/09/19
Sauer AndreaBoblitz LennartDrick NoraWiestler MiriamScharbau MichèlePries PhilippBollmann Benjamin-AlexanderHoeper Marius MPink Isabell - The ongoing COVID-19 pandemic caused by SARS-CoV-2 continues to pose significant challenges to global public health. Small-molecule ligands targeting G-quadruplex (G4) structures have shown considerable potential in antiviral therapy. However, existing studies have largely focused on individual viruses or isolated host systems, primarily employing in vitro or in vivo approaches to examine interactions between specific ligands and particular G4 structures. There remains a need for novel intervention strategies and a deeper mechanistic understanding of G4-ligand interactions to advance rational drug design. - Source: PubMed
Publication date: 2026/08/12
Zhu Long-YuZhu MinAn Lu-YanQiao Jun-QinZheng Wei-JuanShen Ju-WenMao LiLian Hong-Zhen - Reports worldwide on suspected child maltreatment (CM) during and after the COVID-19 pandemic have been inconsistent. As no study has yet systematically examined whether structural disruptions to child protection systems have left measurable and lasting traces in referral patterns beyond the acute crisis phase, this study investigated the pandemic's impact on suspected CM referrals to the Forensic Examination Center for Children and Adolescents (FOKUS) in Vienna, Austria, and whether enduring shifts in CM presentation and referral dynamics have occurred. - Source: PubMed
Publication date: 2026/09/19
Grylli ChryssaKlomfar SophieBrandlechner JohannaSchaller LauraWeimann KatharinaPantazidou AnastasiaMora-Theuer EvaKrall ChristophQuantin CatherineGreber-Platzer Susanne - Sipavibart, a recombinant human immunoglobulin G1-based monoclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, is approved in Japan for prevention of COVID-19 in immunocompromised individuals. This phase 1 study evaluated the safety and pharmacokinetics (PK) of sipavibart in Japanese individuals. - Source: PubMed
Publication date: 2026/09/19
Okada HiroshiShinbo TakumiKim HyosungNoda YoshinoriEto Takashi